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Background. Persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with high
mortality rates, but no treatment strategy has yet been established. We performed this study to evaluate the efficacy
of linezolid with or without carbapenem in salvage treatment for persistent MRSA bacteremia.
Methods. All adult patients with persistent MRSA bacteremia for 7 days from January 2006 through March
2008 who were treated at Seoul National University Hospital were studied. The results of linezolid salvage therapy
with or without carbapenem were compared with those of salvage therapy with vancomycin plus aminoglycosides
or rifampicin.
Results. Thirty-five patients with persistent MRSA bacteremia were studied. The early microbiological response
(ie, negative results for follow-up blood culture within 72 hours) was significantly higher in the linezolid-based
salvage therapy group than the comparison group (75% vs 17%; ). Adding aminoglycosides or rifampicinP p .006
to vancomycin was not successful in treating any of the patients, whereas linezolid-based therapy gave an 88%
salvage success rate ( ). The S. aureus–related mortality rate was lower for patients treated with a linezolidP ! .001
salvage regimen than for patients continually treated with a vancomycin-based regimen (13% vs 53%; ).P p .030
Conclusions. Linezolid-based salvage therapy effectively eradicated S. aureus from the blood for patients with
persistent MRSA bacteremia. The salvage success rate was higher for linezolid therapy than for vancomycin-based
combination therapy.
Staphylococcus aureus is a major cause of community-
acquired and nosocomial infections [1]. The organism
is the second most common cause of nosocomial bac-
teremia in the United States [2]. Glycopeptides have
been used as the main treatment for serious methicillin-
resistant S. aureus (MRSA) infections, including bac-
teremia. However, treatment failure in MRSA infections
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has increased and has become a major clinical problem
[3–5].
Persistent S. aureus bacteremia raises concern be-
cause it occurs despite the administration of appro-
priate antibiotics shown by laboratory tests to be active
in vitro. The microbiological and clinical characteristics
of persistent S. aureus bacteremia have been studied
[6–9], but the mechanism of persistence is still poorly
understood, and no clinical indicator is available to
predict glycopeptide treatment failure. Moreover, no
treatment strategy has been established, despite the fact
that failure is common and frequently leads to death
[8, 9]. The approaches of infectious diseases consultants
to treating persistent MRSA bacteremia have been ex-
amined [10], but no consensus has emerged in relation
to antimicrobial therapy because few clinical data are
available.
Linezolid, an oxazolidinone, is used to treat infec-
tions caused by resistant gram-positive pathogens. Its
efficacy in treating skin and soft-tissue infections, pneu-
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monia, and uncomplicated MRSA bacteremia is not inferior to
that of vancomycin [11]. However, its efficacy in treating en-
docarditis or complicated or persistent bacteremia has not been
clearly defined. Recent studies have shown that the combined
use of linezolid and carbapenem has a synergistic bactericidal
effect on S. aureus in vitro and in an animal endocarditis model
[12, 13], but no clinical data are available. We performed this
study to investigate the incidence and clinical features of per-
sistent S. aureus bacteremia and to estimate the efficacy of
linezolid with or without carbapenem for the salvage treatment
of persistent S. aureus bacteremia.
PATIENTS AND METHODS
Patients. All patients 16 years old with persistent S. aureus
bacteremia from 1 January 2006 through 31 March 2008 were
studied at Seoul National University Hospital (Republic of Ko-
rea), a 1500-bed tertiary care university hospital and referral
center. Patients were identified by reviewing the computerized
records of the Clinical Microbiology Laboratory. Only the first
episode of S. aureus bacteremia in a patient was included in
the study.
Microbiological tests. S. aureus was identified and antibi-
otic resistance was determined with automated systems (Vitek
2, bioMérieux; and Microscan, Dade Behring). Susceptibility
to arbekacin was determined by the disk diffusion method with
30-mg arbekacin disks (Eiken Chemical) and a breakpoint of
18 mm. In cases of MRSA, the minimum inhibitory con-
centration (MIC) of vancomycin was determined by micro-
dilution (BBL Mueller Hinton II Broth [cation adjusted]; BD
Diagnostics) in accordance with the recommendations of the
Clinical and Laboratory Standards Institute [14]. Screening tests
for hetero-vancomycin-intermediate S. aureus (hetero-VISA)
were performed using brain heart infusion agar plates con-
taining 4 mg/mL of vancomycin [15].
Definitions. Persistent bacteremia was defined as the iso-
lation of S. aureus in blood cultures obtained from peripheral
veins on 7 consecutive days despite appropriate antibiotic
administration for 5 days. S. aureus bacteremia was defined
as community associated or as health care associated in ac-
cordance with Centers for Disease Control and Prevention def-
initions [16]. S. aureus infection was defined as catheter related
if the catheter tip yielded 115 colonies for S. aureus or inflam-
mation was present at the insertion site and no alternative
source of infection was identified [17]. Endocarditis was defined
by the modified Duke criteria [18]. Metastatic infection was
defined as the presence of microbiological or radiographic evi-
dence of S. aureus infection caused by hematogenous seeding
[19]. Complicated infection was defined as a site of infection
remote from the primary focus caused by hematogenous seed-
ing, including endocarditis, or extension of the infection be-
yond the primary focus (eg, septic thrombophlebitis or abscess)
[20]. Eradicable foci included surgically removable infections
or drainable abscesses and indwelling foreign bodies, such as
peripheral and central venous catheters. Noneradicable foci in-
cluded unknown primary sites, pneumonia, endocarditis, and
osteomyelitis or arthritis. Noneradicated foci comprised
noneradicable foci and eradicable foci not actually eradicated
[21]. Thirty-day mortality was defined as the death of a patient
without clearance of bacteremia or within 30 days after clear-
ance of bacteremia. Mortality was defined as S. aureus–related
if there was no other definite cause of death.
Salvage attempt and outcome measure. Salvage attempt
was defined as administration of a new antibiotic, active against
the S. aureus isolate in laboratory susceptibility tests, for 72
hours as a substitute or supplement. Linezolid was administered
intravenously at a dosage of 600 mg every 12 hours as salvage
therapy. The efficacy of salvage treatment was evaluated by 2
outcome measures: early microbiological response and salvage
success. Early microbiological response was defined as conver-
sion of positive blood culture results to negative within 72 hours
of antibiotic initiation. Salvage was defined as successful if the
agent used was not subsequently changed because of ineffec-
tiveness and S. aureus–related death did not occur.
Statistical analysis. Categorical variables were compared
using the Fisher exact test or Pearson x2 test, as appropriate,
and continuous variables were compared using the Mann-
Whitney U test. All tests of significance were 2-tailed, and
was considered statistically significant. Statistical anal-P  .05
yses were performed with SPSS, version 12.0 (SPSS).
RESULTS
Prevalence of persistent S. aureus bacteremia. We identified
377 cases of S. aureus bacteremia during the study period. Of
the 377 cases of S. aureus bacteremia, 41 (11%) were persistent
despite administration of appropriate antibiotic. Thirty-five
(17%) of the 211 cases of MRSA bacteremia and 6 (4%) of the
166 cases of methicillin-sensitive S. aureus (MSSA) bacteremia
were persistent ( ). The duration of persistence was 7–P ! .001
10 days (median, 7 days; mean, 7.6 days) for the cases of MSSA
bacteremia and 7–168 days (median, 12 days; mean, 18.1 days)
for the cases of MRSA bacteremia ( ). All the patientsP p .009
with persistent MSSA bacteremia were successfully treated using
nafcillin-penicillin with or without aminoglycoside (plus rifam-
picin in the case of prosthetic valve endocarditis), so salvage
attempt was not applied for them.
Clinical characteristics of persistent MRSA bacteremia. Of
the 35 cases of MRSA bacteremia, 34 were health care associated
(30 nosocomial) and 1 was community associated. The clinical
features of the persistent cases of MRSA bacteremia are given
in tables 1 and 2. The mean age of the patients was 59 years
in the vancomycin-continued group and 70 years in the line-
zolid salvage group ( ). For the 35 patients, diabetesP p .01
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no. (%) of patients
Salvage success,b
no. (%) of patients
Addition of aminoglycosidesc or rifampicind to vancomycin 12 2 (17) 0 (0)
Vancomycin and aminoglycosides 6 0 (0) 0 (0)
Vancomycin and rifampicin 4 1 (25) 0 (0)
Vancomycin, aminoglycosides, and rifampicin 2 1 (50) 0 (0)
Substitution of linezolid for vancomycin 16 12 (75) 14 (88)
Linezolid 7 5 (71) 7 (100)
Linezolid and carbapenem 9 7 (78) 7 (78)
a Negative results for follow-up blood culture within 72 h after administration of salvage antibiotic ( , derived by comparing additionP p .006
of aminoglycosides or rifampicin to vancomycin with substitution of linezolid for vancomycin).
b (derived by comparing addition of aminoglycosides or rifampicin to vancomycin with substitution of linezolid for vancomycin).P ! .001
c Gentamicin was used in 2 cases in which the isolates were susceptible to gentamicin, whereas arbekacin was used in the other cases
in which the isolates were resistant to gentamicin but susceptible to arbekacin.
d Rifampicin was used in 6 cases in which the isolates were susceptible to rifampicin.







no. (%) of patients
30-day mortality,b
no. (%) of patients
Vancomycin-continue group 19 10 (53) 10 (53)
Vancomycin 14 6 (43) 6 (43)
Vancomycin and aminoglycosides or rifampicin 5 4 (80) 4 (80)
Linezolid salvage group 16 2 (13) 4 (25)
Linezolid 7 0 (0) 2 (29)
Linezolid and carbapenem 9 2 (22) 2 (22)
a (derived by comparison of the vancomycin-continue group and linezolid salvage group).P p .030
b (derived by comparison of the vancomycin-continue group and linezolid salvage group).P p .166
mellitus (in 12 patients [34%]), end-stage renal disease (in 10
[29%]), solid cancers (in 10 [29%]), and the presence of vas-
cular grafts (in 11 [31%]) were common as underlying disease.
Endovascular infection (in 19 patients [54%]), especially of a
central catheter (in 15 [43%]), was the most common primary
site of infection. Twenty-eight (80%) of the cases were com-
plicated S. aureus infections. Infected venous thrombus and
abscess were detected in 7 (20%) and 14 (40%) of the cases,
respectively. Transthoracic echocardiography and transesopha-
geal echocardiography were performed in 30 (86%) and 13
(37%) of the patients with MRSA bacteremia, respectively. En-
docarditis was detected in 6 patients (17%). Metastatic foci
were observed in 20 patients (57%), and common metastatic
foci were endovascular structures (endocardium or vascular
grafts) (in 9 patients), spine (in 8), brain (in 7), lung (in 5),
and pleura (in 2). Although adjunct therapy to remove foci
was performed in 25 patients (71%), noneradicated foci re-
mained in 30 patients (86%). Underlying diseases, primary site
of infection, rates of complicated and metastatic infection, and
noneradicated foci were not significantly different in the van-
comycin-continued and linezolid salvage groups.
Among the 35 MRSA isolates causing persistent bacteremia,
the vancomycin MIC was 2 mg/mL in 3 isolates. No VISA was
observed. Four isolates (11%) showed growth on brain heart
infusion agar with 4 mg/mL of vancomycin. Resistance to gen-
tamicin and rifampicin was observed in 25 (71%) and 3 (9%)
of the cases, respectively. All the isolates were susceptible to
linezolid and arbekacin. MRSA bacteremia was persistent, al-
though the serum vancomycin trough concentration exceeded
10 mg/mL in 31 (91%) and 15 mg/mL in 19 (56%) of the 34
cases evaluated in our study.
Salvage antibiotic attempts and outcomes for patients with
persistent MRSA bacteremia. The salvage attempts against
persistent MRSA bacteremia and their consequences are sum-
marized in tables 3 and 4. Early microbiological responses and
salvage success rates were significantly higher with the linezolid-
based regimen than with the comparators ( andP p .006 P !
, respectively). Adding aminoglycosides or rifampicin to.001
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vancomycin was not successful in any case. However, linezolid-
based therapy had a salvage success rate of 88%. A linezolid-
based regimen was introduced for 6 patients who had treatment
failure despite the addition of aminoglycosides or rifampicin.
One of these patients died without a microbiological response,
but 4 of the others became culture negative within 72 hours
and the remaining patient within a week. These 5 patients were
successfully treated.
The 30-day mortality rate was 40% (14 patients) and the S.
aureus–related mortality rate was 34% (12 patients) for the 35
patients with persistent MRSA bacteremia. The S. aureus–re-
lated mortality rate was significantly lower for patients who
were treated with a linezolid salvage regimen than for patients
who were continuously treated with a vancomycin-based reg-
imen (53% vs 13%; ; table 4).P p .03
Adverse reactions to linezolid-based therapy. Seven (58%)
of 12 evaluable patients had linezolid-associated thrombocy-
topenia during use of the antibiotic. Thrombocytopenia de-
veloped 7–21 days after the initiation of antibiotic treatment.
Linezolid-based regimens were changed to vancomycin with or
without rifampicin in 7 patients. Of these, 5 were successfully
treated. However, recurrence of bacteremia was observed in 2
patients, and they were successfully treated by readministration
of linezolid with or without carbapenem.
DISCUSSION
In the present study, we found that linezolid-based salvage
therapy was effective in eradicating S. aureus from the blood
within 72 hours for patients with persistent MRSA bacteremia.
We also showed that the salvage success rate was higher with
linezolid-based therapy than with vancomycin-based combi-
nation therapy. The rate of persistence of S. aureus bacteremia
was 11% during the study period in our hospital. This figure
had not increased: it was 13% (31 of 238 patients with S. aureus
bacteremia) in our previous investigation from January 1998
to October 2001 [22]. The prevalence in our hospital was sim-
ilar to that in another center, with 11% of persistent bacteremia
for 7 days [9]. Persistence was more common in MRSA bac-
teremia than in MSSA bacteremia, which agrees with previous
studies [8, 9].
Some investigators have reported cases of persistent bacter-
emia caused by VISA or hetero-VISA [23, 24]. However, we
found no VISA, and only 4 isolates were positive on the hetero-
VISA screening test. In addition, only a few isolates had a
vancomycin MIC of 2 mg/mL. Similar findings were obtained
in other studies [7, 8]. Adequate vancomycin serum concen-
tration is important to eradicate MRSA from infected sites.
However, MRSA bacteremia persisted even though serum van-
comycin trough concentrations exceeded 10 mg/mL in most of
the patients evaluated in our study. Some authors have pro-
posed that it is important to achieve serum vancomycin trough
concentrations of 115 mg/mL to achieve better treatment out-
comes in MRSA infections [25]. However, 56% of our patients
had persistent bacteremia despite the fact that their serum van-
comycin trough concentrations were 115 mg/mL.
Approximately 70% of infectious diseases consultants in the
United States reported that they preferred to continue admin-
istration of vancomycin and add aminoglycoside or rifampicin
for persistent MRSA bacteremia if the vancomycin MIC did
not exceed 2 mg/mL [10]. We also used these agents in addition
to vancomycin for patients with persistent MRSA bacteremia
that did not response to vancomycin monotherapy. Of the
aminoglycosides, gentamicin was used for 2 patients, whereas
arbekacin was used for the patients for whom the isolates were
resistant to gentamicin but susceptible to arbekacin [26]. How-
ever, these attempts were unsuccessful: combination therapy
was ineffective for most of the patients for whom vancomycin
alone had failed to eradicate S. aureus from the blood.
The success rate of salvage attempts with linezolid-based
regimens was 88% in the present study, and similar success
rates have been reported in previous studies [24, 27]. Although
the number of cases was small, linezolid seemed to be effective
as salvage therapy in our study, even though the regimen was
introduced for patients for whom vancomycin-based combi-
nation therapy had already failed or who had had persistent
MRSA bacteremia for a prolonged period or who had multiple
metastatic sites. We chose ertapenem for combination therapy
in our study because it has the narrowest spectrum among
carbapenems.
Various new antibiotics could be considered candidates for
the treatment of persistent MRSA bacteremia [28]. However,
good penetration of the antibiotic into the tissues of the body,
especially lung, bone, and brain, and if possible into biofilms,
abscesses, thrombi, and cardiac vegetations is essential, because
devices, abscesses, thrombi, endocarditis, and metastatic foci at
various sites were shown in our study and in others [8, 9] to
be implicated in bacteremic persistence. We tried linezolid and
carbapenem, which synergize, because both have good tissue-
penetration properties.
Although the efficacy of linezolid-based regimens was good,
thrombocytopenia limited their prolonged use for the 4 weeks
that are needed to treat complicated S. aureus bacteremia [1].
The incidence of thrombocytopenia in our study was high,
probably because of the high proportion of serious underlying
diseases and end-stage renal disease for patients with persistent
bacteremia [29]. Although the duration of linezolid therapy
was shortened by thrombocytopenia, the subsequent use of
vancomycin for a total of 4–6 weeks after negative blood culture
results were achieved was successful.
The present study has methodological limitations because
it was retrospective in design. Hence, regimen, starting point,
and duration of salvage therapy were not uniform. Because the
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factors influencing the physicians’ choice of antibiotics were
not determined, they may have influenced our results as un-
measured confounding factors in the analysis. Also, the sample
size was limited and too small to distinguish between the ef-
fectiveness of linezolid-carbapenem combination therapy and
linezolid monotherapy. The prevalence of endocarditis was pos-
sibly underestimated because transesophageal echocardiogra-
phy was performed in only 37% of the patients. Despite such
limitations, our data provide some valuable information that
can affect treatment strategy. No clinical data were previously
available on the outcome of salvage therapy that compared the
use of alternative agents with the addition of aminoglycosides
or rifampicin to vancomycin for patients with persistent MRSA
bacteremia. Moreover, the clinical outcome of combination
treatment with linezolid and carbapenem for patients with per-
sistent MRSA bacteremia was defined for the first time.
In summary, for treating persistent MRSA bacteremia, the
substitution of alternative agents for vancomycin appeared to
be preferable to the addition of rifampicin or aminoglycoside
to vancomycin, even if the isolate involved has been reported
by current laboratory tests to be susceptible to vancomycin.
Linezolid with or without carbapenem can be an effective sal-
vage option, producing better outcomes for patients with per-
sistent MRSA bacteremia.
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